The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma

  • Yoo, Chang-Hoon (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Shin (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Sohn, Byeong-Seok (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Jeong-Eun (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yoon, Dok-Hyun (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Huh, Joo-Ryung (Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Dae-Ho (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Sang-We (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Jung-Shin (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Suh, Cheol-Won (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2009.12.14
  • Accepted : 2010.04.05
  • Published : 2010.09.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP) has improved survival in patients with diffuse large B-cell lymphoma (DLBCL) and weakened the prognostic power of the international prognostic index (IPI). We evaluated the efficacy of the IPI and revised IPI (R-IPI) in patients with DLBCL who were treated with R-CHOP, focusing on extranodal site number (ENS) because extranodal involvement occurs frequently in Koreans. Methods: A total of 126 R-CHOP-treated patients with stage III/IV DLBCL were analyzed. We performed a retrospective analysis of the clinicopathologic factors and verified the predictive power of the standard IPI and RIPI. Various numbers of extranodal sites were analyzed for further stratification, and we set the extranodal sitemodified IPI (E-IPI) as the IPI when the number of extranodal sites was stratified as < 3 vs. ${\geq}$ 3. Results: A univariate analysis showed that ENS was associated with complete response (CR, p = 0.04), eventfree survival (EFS, p = 0.01), and overall survival (OS, p < 0.001) when the ENS cut-off was set at ≥ 3. A multivariate analysis revealed that an ENS ${\geq}$ 3 remained associated with EFS (p < 0.01; hazard ratio [HR], 2.60; 95% confidence interval [CI], 1.29 to 5.26) and OS (p < 0.01; HR, 3.52; 95% CI, 1.68 to 7.35). The IPI was effective for determining prognosis in terms of OS (p = 0.04) but not EFS (p = 0.17). The R-IPI was effective in terms of both variables (p = 0.02 and 0.04, respectively), as was the E-IPI (p = 0.01 and 0.001, respectively). Conclusions: An ENS < 3 vs. ${\geq}$ 3, rather than the original < 2 vs. ${\geq}$ 2, was the most significant prognostic factor for EFS and OS. All three indices were predictive, but only the E-IPI identified the high-risk group of R-CHOP-treated Korean patients with disseminated DLBCL.

Keywords

References

  1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002-1006. https://doi.org/10.1056/NEJM199304083281404
  2. Park YH, Lee JJ, Ryu MH, et al. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol 2006;85:257-262. https://doi.org/10.1007/s00277-005-0060-6
  3. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391. https://doi.org/10.1016/S1470-2045(06)70664-7
  4. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126. https://doi.org/10.1200/JCO.2005.09.131
  5. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995-1007. https://doi.org/10.1200/JCO.2005.02.4786
  6. Hermans J, Krol AD, van Groningen K, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995;86:1460-1463.
  7. Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features: Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998;83:806-812. https://doi.org/10.1002/(SICI)1097-0142(19980815)83:4<806::AID-CNCR26>3.0.CO;2-V
  8. Greiner TC, Medeiros LJ, Jaffe ES. Non-Hodgkin's lymphoma. Cancer 1995;75(1 Suppl):370-380.
  9. Ho FC, Todd D, Loke SL, Ng RP, Khoo RK. Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients, retrospective study covering an eight-year period. Int J Cancer 1984;34:143-148. https://doi.org/10.1002/ijc.2910340202
  10. Hahn JS, Lee S, Chong SY, Min YH, Ko YW. Eight-year experience of malignant lymphoma: survival and prognostic factors. Yonsei Med J 1997;38:270-284.
  11. Kim HT, Im YH, Suh CI, et al. Malignant lymphomas in Korea. J Korean Cancer Assoc 1992;24:92-101.
  12. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-4284. https://doi.org/10.1182/blood-2002-11-3442
  13. Wilson KS, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:1102-1109. https://doi.org/10.1080/10428190701344881
  14. Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008;49:462-469. https://doi.org/10.1080/10428190701809156
  15. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861. https://doi.org/10.1182/blood-2006-08-038257
  16. Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008;19:1921-1926. https://doi.org/10.1093/annonc/mdn392
  17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
  18. Ko OB, Jang G, Kim S, Huh J, Suh C. Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement. Korean J Intern Med 2008;23:182-190. https://doi.org/10.3904/kjim.2008.23.4.182

Cited by

  1. Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphoma vol.97, pp.2, 2013, https://doi.org/10.1007/s12185-013-1260-9
  2. Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study vol.2013, pp.None, 2010, https://doi.org/10.1155/2013/908191
  3. The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis vol.11, pp.4, 2015, https://doi.org/10.5114/aoms.2015.53289
  4. Outcome prediction by extranodal involvement, IPI, R‐IPI, and NCCN‐IPI in the PET/CT and rituximab era: A Danish–Canadian study of 443 patients with diffuse‐large B‐cell vol.90, pp.11, 2015, https://doi.org/10.1002/ajh.24169
  5. Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement vol.17, pp.None, 2010, https://doi.org/10.1186/s12885-017-3113-z
  6. Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial vol.107, pp.4, 2018, https://doi.org/10.1007/s12185-018-2403-9
  7. Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India vol.17, pp.4, 2021, https://doi.org/10.4103/jcrt.jcrt_428_19